T. Rowe Price Associates’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-202,466
| Closed | -$187K | – | 3292 |
|
|
2026
Q1 | $187K | Buy |
202,466
+30,332
| +18% | +$36.7K | ﹤0.01% | 2865 |
|
|
2025
Q4 | $221K | Buy |
172,134
+14,592
| +9% | +$19.6K | ﹤0.01% | 2778 |
|
|
2025
Q3 | $205K | Sell |
157,542
-52,119
| -25% | -$68.3K | ﹤0.01% | 2786 |
|
|
2025
Q2 | $252K | Buy |
209,661
+14,193
| +7% | +$15.7K | ﹤0.01% | 2606 |
|
|
2025
Q1 | $212K | Buy |
195,468
+14,000
| +8% | +$19.7K | ﹤0.01% | 2609 |
|
|
2024
Q4 | $318K | Buy |
181,468
+16,475
| +10% | +$30.7K | ﹤0.01% | 2485 |
|
|
2024
Q3 | $319K | Sell |
164,993
-50
| -0% | -$98 | ﹤0.01% | 2449 |
|
|
2024
Q2 | $293K | Buy |
165,043
+96,174
| +140% | +$235K | ﹤0.01% | 2424 |
|
|
2024
Q1 | $187K | Buy |
68,869
+42,069
| +157% | +$102K | ﹤0.01% | 2641 |
|
|
2023
Q4 | $60K | Sell |
26,800
-11,600
| -30% | -$24.8K | ﹤0.01% | 2781 |
|
|
2023
Q3 | $112K | Hold |
38,400
| – | – | ﹤0.01% | 2639 |
|
|
2023
Q2 | $75K | Sell |
38,400
-12,300
| -24% | -$24.3K | ﹤0.01% | 2745 |
|
|
2023
Q1 | $99K | Sell |
50,700
-34,200
| -40% | -$67.6K | ﹤0.01% | 2690 |
|
|
2022
Q4 | $99K | Buy |
84,900
+23,100
| +37% | +$28.4K | ﹤0.01% | 2722 |
|
|
2022
Q3 | $68K | Buy |
61,800
+44,100
| +249% | +$66.7K | ﹤0.01% | 2790 |
|
|
2022
Q2 | $28K | Sell |
17,700
-6,961
| -28% | -$17.2K | ﹤0.01% | 2913 |
|
|
2022
Q1 | $89K | Buy |
24,661
+1,900
| +8% | +$6.56K | ﹤0.01% | 2867 |
|
|
2021
Q4 | $89K | Sell |
22,761
-28,300
| -55% | -$132K | ﹤0.01% | 2888 |
|
|
2021
Q3 | $336K | Sell |
51,061
-7,781
| -13% | -$51.2K | ﹤0.01% | 2539 |
|
|
2021
Q2 | $362K | Buy |
58,842
+1,970
| +3% | +$10.5K | ﹤0.01% | 2524 |
|
|
2021
Q1 | $257K | Sell |
56,872
-19,845
| -26% | -$109K | ﹤0.01% | 2613 |
|
|
2020
Q4 | $460K | Buy |
76,717
+43,800
| +133% | +$288K | ﹤0.01% | 2275 |
|
|
2020
Q3 | $245K | Buy |
+32,917
| New | +$227K | ﹤0.01% | 2364 |
|
|
2017
Q4 | – | Sell |
-14,900
| Closed | -$75K | – | 2592 |
|
|
2017
Q3 | $75K | Hold |
14,900
| – | – | ﹤0.01% | 2527 |
|
|
2017
Q2 | $60K | Hold |
14,900
| – | – | ﹤0.01% | 2519 |
|
|
2017
Q1 | $85K | Hold |
14,900
| – | – | ﹤0.01% | 2506 |
|
|
2016
Q4 | $108K | Hold |
14,900
| – | – | ﹤0.01% | 2463 |
|
|
2016
Q3 | $119K | Sell |
14,900
-8,100
| -35% | -$74.4K | ﹤0.01% | 2424 |
|
|
2016
Q2 | $208K | Hold |
23,000
| – | – | ﹤0.01% | 2311 |
|
|
2016
Q1 | $186K | Hold |
23,000
| – | – | ﹤0.01% | 2306 |
|
|
2015
Q4 | $249K | Buy |
+23,000
| New | +$226K | ﹤0.01% | 2222 |
|
Other funds holding LAB
CC
MCO
LFCM
HBWM
RA
T. Rowe Price Associates's LAB Position: Q2 2026 in Review
T. Rowe Price Associates sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 202,466 shares — an estimated $187K sold.
T. Rowe Price Associates first reported a position in LAB in Q4 2015 and held it in 31 quarters. The position peaked at $460K in Q4 2020. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.
- T. Rowe Price Associates reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
- T. Rowe Price Associates sold 202,466 Standard BioTools shares in Q2 2026, an estimated $187K.
- T. Rowe Price Associates first reported a position in Standard BioTools in Q4 2015 and held it in 31 quarters.
- T. Rowe Price Associates's Standard BioTools position peaked at $460K in Q4 2020.
- 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.